|
| |
AchillionAchillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion’s drug development pipeline is led by elvucitabine (Beta-L-Fd4C or ACH-126,443), which is currently in late-stage Phase 2 clinical trials for the treatment of patients infected with HIV. Achillion’s candidate for the potential treatment of HCV infection, ACH-806, is in a Phase 1 clinical trial and is anticipated to be completed by the first half of 2006.
| Contact Details: |
| 300 George Street |
| New Haven, |
| Connecticut |
| 06511 |
| United States of America |
| Tel: | 203-624-7000 |
| Fax: | 203-624-7003 |
| Email: | info@achillion.com |
| WWW: | www.achillion.com/
|
|
Loading...
|
Recent Publications by Achillion: |  |
A highly sensitive and reproducible HCV RNA hybridization method valuable for antiviral drug discovery.
Real-time RT-PCR and Northern blot are employed for the measurement of HCV... | 20th September, 2008
| Achillion Pharmaceuticals, 300 George Street, New Haven, CT 06511, USA.
| J Virol Methods. 2008 Jul;151(1):154-7. Epub 2008 May 8.
DOI Direct Link |
Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
We have discovered a novel class of compounds active against hepatitis C... | 17th July, 2008
| Achillion Pharmaceuticals, New Haven, CT 06511, USA.
| Antimicrob Agents Chemother. 2008 Jun;52(6):2043-52. Epub 2008 Apr 14.
DOI Direct Link |
Recent advances in bacterial topoisomerase inhibitors.
Bacterial topoisomerase inhibitors continue to be actively developed as... | 17th June, 2008
| Achillion Pharmaceuticals, Inc., 300 George Street, New Haven, CT 06511,
| Curr Opin Pharmacol. 2008 Jun 12.
DOI Direct Link |
A method to assay penicillin-binding proteins.
Key enzymes that assemble the bacterial cell wall are also the target of... | 23rd May, 2008
| Achillion Pharmaceuticals, New Haven, CT, USA.
| Methods Mol Med. 2008;142:131-41.
DOI Direct Link |
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Heteroaryl isothiazolones (HITZs) are antibacterial agents that display... | 31st October, 2007
| Achillion Pharmaceuticals, New Haven, CT 06511, USA.
| Antimicrob Agents Chemother. 2007 Jul;51(7):2445-53. Epub 2007 May 14.
DOI Direct Link |
→View more Achillion research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 187 times since April 2007, the link to the organisation's website has been followed 28 times Recent Search Terms used to find this page: achillion topoisomerase contacts | achillion.com | . Search for more companies in New Haven, Search for more companies in Connecticut This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Achillion |
